PrEP Assistance Program Act
Summary
HR7385 is an early-stage bill authorizing up to $10M per grant for PrEP programs, with no specified total funding or direct corporate beneficiaries. It has been referred to committee with 14 cosponsors, all Democrats. At this procedural stage, the bill has no measurable market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7385 is an early-stage authorization bill with zero appropriated funding
- 2.All 14 cosponsors are Democrats—low passage probability in Republican-controlled House
- 3.No direct corporate beneficiaries; the funding mechanism is grants to eligible entities, not contracts to drug manufacturers
Market Implications
No market implications at this stage. The bill is purely procedural. If it advanced to a committee markup with a specified funding amount ($500M+), Gilead Sciences ($GILD) would be the primary beneficiary as the dominant PrEP manufacturer. But that scenario requires the bill to pass a Republican House and be signed into law—a low-probability event. No action required for retail investors.
Full Analysis
HR7385, the PrEP Assistance Program Act, was introduced on February 4, 2026, and referred to the House Committee on Energy and Commerce. The bill authorizes the CDC and HRSA to establish a grant program for pre-exposure prophylaxis (PrEP) for HIV prevention, with grants capped at $10 million per eligible entity. No total appropriation is specified; this is an authorization-only bill. Actual funding would require a separate appropriations bill.
The bill has 14 cosponsors, all Democrats, and no Republican cosponsors. The sponsor, Rep. Watson Coleman (D-NJ), is a junior member without committee leadership. The bill is in the earliest legislative stage—no hearings, no markup, no CBO score. Passage probability in the Republican-controlled House is extremely low.
No executive actions are relevant to this bill. The DPA memoranda on energy infrastructure (Apr 20, 2026) have no connection to HIV prevention grant programs.
There are no publicly traded companies that derive material revenue from PrEP grant programs. PrEP drugs (Truvada, Descovy, Apretude) are manufactured by Gilead Sciences ($GILD) and ViiV Healthcare (GSK, $GSK), but this grant program does not mandate purchasing, name drug manufacturers, or allocate specific funding. The mechanism is grants to community organizations and health departments—not direct contracts to pharmaceutical companies. The $10M per-grant cap is too small to move stock prices for any public company.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to increase access to pre-exposure prophylaxis to reduce the transmission of HIV.
PrEP Access and Coverage Act of 2026
PrEP and PEP are Prevention Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →